Practical synthesis of (R)-4-mercaptopyrrolidine-2-thione from L- aspartic acid. Preparation of a novel orally active 1-β-methylcarbapenem, TA-949

Journal of Organic Chemistry

Volumn 65, Issue 2, 2000, Pages 517-522

  Seki, Masahiko ^a   Yamanaka, Takeshi ^a   Kondo, Kazuhiko ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; PYRROLIDINE DERIVATIVE; TA 949; UNCLASSIFIED DRUG;

AMINATION; ANTIBACTERIAL ACTIVITY; ARTICLE; BROMINATION; CYCLIZATION; ESTERIFICATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ASPARTIC ACID; CARBAPENEMS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PYRROLIDINES; SPECTROPHOTOMETRY, INFRARED; THIONES;

EID: 0034723280     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo991461+     Document Type: Article

References (24)

1. For example see: (a) Shih, D. H.; Baker, F.; Cama, L.; Christensen, B. G. Heterocycles 1984, 21, 29. (b) Sunagawa, M.; Matsumura, H.; Inoue, T.; Fukasawa, M.; Kato, M. J. Antibiot. 1990, 43, 519. (c) Petersen, P. J.; Jacobus, N. V.; Weise, W. J; Testa, R. T. Antimicrob. Agents Chemother. 1991, 35, 203.
2. For example see: (a) Shih, D. H.; Baker, F.; Cama, L.; Christensen, B. G. Heterocycles 1984, 21, 29. (b) Sunagawa, M.; Matsumura, H.; Inoue, T.; Fukasawa, M.; Kato, M. J. Antibiot. 1990, 43, 519. (c) Petersen, P. J.; Jacobus, N. V.; Weise, W. J; Testa, R. T. Antimicrob. Agents Chemother. 1991, 35, 203.
3. For example see: (a) Shih, D. H.; Baker, F.; Cama, L.; Christensen, B. G. Heterocycles 1984, 21, 29. (b) Sunagawa, M.; Matsumura, H.; Inoue, T.; Fukasawa, M.; Kato, M. J. Antibiot. 1990, 43, 519. Petersen, P. J.; Jacobus, N. V.; Weise, W. J; Testa, R. T. Antimicrob. Agents Chemother. 1991, 35, 203.
4. (a) Rossi, T.; Biondi, S.; Contini, S.; Thomas, R. J.; Marchioro, C. J. Am. Chem. Soc. 1995, 117, 9604.
5. (b) Miyauchi, M.; Endo, R.; Hisaoka, M.; Yasuda, H.; Kawamoto, I. J. Antibiot. 1997, 50, 429.
6. (a) Iwasaki, T.; Kondo, K.; Horikawa, H.; Yamaguchi, T.; Matsushita, T. U.S. Patent 5153187, Oct 6, 1992.
7. (b) Seki, M.; Kondo, K.; Iwasaki, T. 13th French-Japanese Symposium on Medicinal and Fine Chemistry, Hayama, Japan, May 25-28, 1998; Abstract P-12.
8. (a) Seki, M.; Miyake, T.; Yamanaka, T.; Ohmizu, H. Synlett 1996, 455.
9. (b) Seki, M.; Yamanaka, T.; Miyake, T.; Ohmizu, H. Tetrahedron Lett. 1996, 37, 5565.
10. (c) Seki, M.; Furutani, T.; Miyake, T.; Yamanaka, T.; Ohmizu, H. Tetrahedron: Asymmetry 1996, 7, 1241.
11. (a) Kondo, K,; Seki, M.: Kuroda, T.; Yamanaka, T.; Iwasaki, T. J. Org. Chem. 1995, 60, 1096.
12. (b) Kondo, K,; Seki, M.: Kuroda, T.; Yamanaka, T.; Iwasaki, T. J. Org. Chem. 1997, 62, 2877.
13. (a) Seki, M.; Kondo, K.; Iwasaki, T. Synlett 1995, 315.
14. (b) Seki, M.; Kondo, K.; Iwasaki, T. J. Chem. Soc., Perkin Trans. 1 1996, 2851.
15. Seki, M.; Kondo, K. Synthesis 1999, 745.
16. Kobayashi, S.; Kobayashi, K.; Hirai, K. Synlett 1999, 909.
17. For reviews on the utilization of aspartic acid in drug synthesis see: (a) Matsumoto, K.; Seki, M. J. Synth. Org. Chem. Jpn. 1991, 49, 26. (b) Seki, M.; Matsumoto, K. Bioindustry 1995, 12 (6), 5.
18. For reviews on the utilization of aspartic acid in drug synthesis see: (a) Matsumoto, K.; Seki, M. J. Synth. Org. Chem. Jpn. 1991, 49, 26. (b) Seki, M.; Matsumoto, K. Bioindustry 1995, 12 (6), 5.
19. Murakami, Y.; Koga, K.; Yamada, S. Chem. Pharm. Bull. 1978, 26, 307.
20. Strijtveen, B.; Kellog, R. M. Tetrahedron 1987, 43, 5039.
21. Koh, K.; Ben, R. N.; Durst, T. Tetrahedron Lett. 1994, 35, 375.
22. 2-type elimination was observed in the zinc reagent derived from L-serine: Jackson, R. F. W.; Moore, R. J.; Dexter, C. S. J. Org. Chem. 1998, 63, 7875.
23. Seki, M.; Kondo, K.; Kuroda, T.; Yamanaka, T.; Iwasaki, T. Synlett 1995, 609.
24. The X-ray data of TA-949 (1) have been deposited at the Cambridge Crystallographic Data Centre.